CARE™ CLL Case Study Series

Prevention and Management of Tumour Lysis Syndrome (TLS)

Issue 3

Hematology

13 Jul 2020

About Issue 3

Welcome to the 3rd issue in the CARE™ CLL Case Study Series. This series provides context and guidance on how to navigate some of the challenges that specialists may face in routine practice. Issue 3 explores appropriate prevention of tumour lysis syndrome (TLS) with a modified titration schedule for starting patients on venetoclax. Profile and discussion follow.

Other Issues in the Series:

Issue 1 (Parts 1 & 2) explored identification and management of relapse after BTK inhibition. These publications are also available for download.

Issue 2 focuses on management of relapse after up-front chemoimmunotherapy. Profile and discussion content follows.